TRANSCRIPTIONAL ACTIVATION OF A RETROVIRUS ENHANCER BY CBF (AML1) REQUIRES A 2ND FACTOR - EVIDENCE FOR COOPERATIVITY WITH C-MYB

Authors
Citation
Al. Zaiman et J. Lenz, TRANSCRIPTIONAL ACTIVATION OF A RETROVIRUS ENHANCER BY CBF (AML1) REQUIRES A 2ND FACTOR - EVIDENCE FOR COOPERATIVITY WITH C-MYB, Journal of virology, 70(8), 1996, pp. 5618-5629
Citations number
108
Categorie Soggetti
Virology
Journal title
ISSN journal
0022538X
Volume
70
Issue
8
Year of publication
1996
Pages
5618 - 5629
Database
ISI
SICI code
0022-538X(1996)70:8<5618:TAOARE>2.0.ZU;2-E
Abstract
Transcriptional enhancer sequences within the long terminal repeats (L TRs) of murine leukemia viruses are the primary genetic determinants o f the tissue specificity and potency of the oncogenic potential of the se retroviruses. SL3-3 (SL3) is a murine leukemia virus that induces T -cell lymphomas. The LTR enhancer of this virus contains two binding s ites for the transcription factor CBF (also called AML1 and PEBP2) tha t flank binding sites for c-Myb and the Ets family of factors. Using c otransfection assays in P19 cells, we report here that CBF and c-Myb c ooperatively stimulate transcription from the SL3 LTR. By itself, c-My b had no stimulatory effect on transcription. However, when cotransfec ted with a cDNA encoding one form of the alpha subunit of CBF called C BF alpha 2-451, a level of transactivation higher than that seen with CBF alpha 2-451 alone was detected. The negative regulatory domain nea r the carboxyl terminus of c-Myb did not affect this activity. Electro phoretic mobility shift assays indicated that CBF and c-Myb bind to DN A independently. Therefore, it appears that the cooperative stimulatio n of transcription by these factors occurs at a step in the process of transcription after the two factors are bound to the enhancer. Sequen ces near the carboxyl terminus of CBF alpha 2-451 were important for c ooperativity with c-Myb, consistent with previous reports that this re gion contains an activation domain. However, CBF alpha 2-451 failed to activate transcription from a version of the SL3 LTR in which the enh ancer was replaced with five tandem CBF-binding sites. Thus, it appear s that transcriptional activation of the SL3 enhancer by CBF requires that an appropriate heterologous transcription factor be bound to a ne ighboring site in the regulatory sequences.